Search results: (10000)
News Fatigue in Multiple Sclerosis: What Can Teriflunomide Do?
An article by French authors published in January this year in the journal Multiple Sclerosis and Related Disorders evaluated the effect of teriflunomide on fatigue in patients with multiple sclerosis in real-world practice.
News Role and Possibilities of Telemedicine in the Management of Hemophilia Care
A team of Irish experts recently evaluated the current possibilities of telemedicine in the care of individuals with hemophilia – not only from the perspective of care provided by specialized comprehensive centers but also considering physiotherapy and dental care.
News Manual Fascial Therapy in Patients with Hemophilic Arthropathy
Fascial therapy is a rehabilitative technique that mobilizes the fascial complex using manual techniques with the goal of improving tissue mobility and function, as well as influencing pain. A team of experts from Spain evaluated the safety of this method in hemophiliacs with developed arthropathy in their study.
News What FVIII Levels Are Ideal for Preventing Bleeding in Hemophilia A?
Recent studies indicate that target trough levels of factor 1–3% during prophylactic treatment are insufficient to fully prevent clinical and subclinical bleeding. With a sustained FVIII level > 15%, as shown in studies with mild hemophiliacs, spontaneous bleeding is very rare. This raises the question of whether achieving zero bleeding incidence with FVIII replacement therapy is possible and whether it can be a realistic goal. This topic was also explored in a presentation by Dr. Ester Zápotocká from the Clinic of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and Motol University Hospital in Prague.
News Liposomal Pegylated Irinotecan in the Treatment of Pancreatic Tumors
Combined treatment with liposomal pegylated irinotecan, 5-fluorouracil (5-FU), and leucovorin (LV) significantly improves overall survival in patients with metastatic ductal carcinoma of the pancreas. Analysis of the NAPOLI clinical trial revealed prognostic markers for long-term survival in patients treated this way.
News New Treatment Option for Metastatic Pancreatic Cancer – Pegylated Liposomal Irinotecan
The 2019 review article is dedicated to the use of nanoliposomal irinotecan, its toxicity, and its potential use in the treatment sequence of metastatic pancreatic ductal adenocarcinoma.
News Treatment of Motor Symptoms of Parkinson's Disease
Parkinson's disease (PD) is one of the few neurodegenerative disorders for which effective symptomatic treatment is available. Unfortunately, causal or even neuroprotective therapy with proven efficacy does not yet exist, but properly chosen symptomatic therapy can positively influence the motor manifestations of the disease and significantly improve the patient's quality of life.
News Efficacy and Safety of Axitinib in Higher Lines of Renal Carcinoma Treatment in Real Practice
Greek authors published a retrospective study from a single institution and demonstrated that axitinib is a safe and effective treatment option for metastatic renal carcinoma even in ≥ 3rd line treatment.
News Does dabigatran use in women with acute venous thromboembolism reduce the risk of uterine bleeding compared to warfarin?
The use of new oral anticoagulants (NOACs) in patients with deep vein thrombosis is associated with a more favorable safety profile compared to warfarin. However, direct factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) pose a higher risk of abnormal uterine bleeding. The study presented below compared the risk of this bleeding when using dabigatran (a direct thrombin inhibitor) and warfarin.
News Why Are Mucolytics Beneficial for Patients with COPD?
Part of the clinical picture of chronic obstructive pulmonary disease (COPD) includes mucus hypersecretion in the airways and its impaired clearance, resulting in a chronic productive cough. Mucus production requires management, just like dyspnea and cough. But what can be expected from mucolytic treatment?
News Impact of the COVID-19 Pandemic on People with Schizophrenia Spectrum Disorders
The COVID-19 pandemic has a far-reaching impact on the physical and mental health of the global population. The current situation poses an undue burden on patients suffering from schizophrenia as well as other psychiatric disorders. According to recent studies, individuals with schizophrenia spectrum disorders have higher mortality rates and worsening disease progression or overall quality of life.
News Safety and Effectiveness of Lurasidone in Adolescents with Schizophrenia
An open-label extension of a placebo-controlled study involving 271 patients aged 13–17 years with schizophrenia showed minimal impact on body weight, lipid levels, prolactin, and blood glucose during 2 years of treatment while maintaining and deepening the alleviation of schizophrenia symptoms.
News Diabetic Nephropathy and COVID-19: Fatal Connection?
People with diabetes and diabetic kidney disease exhibit higher mortality and risk of severe illness in connection with COVID-19. The worse prognosis of these patients likely has multiple reasons; in the following overview, we will focus mainly on the cellular receptor of the SARS-CoV-2 virus – angiotensin-converting enzyme 2 (ACE2).
News Alpha-1-Antitrypsin Deficiency and Its Association with Atopy in Asthmatics
Literature mentions the coincidence of asthma and alpha-1-antitrypsin deficiency, which is caused by a mutation in the SERPINA1 gene. The aim of the study presented below was to determine whether the clinical symptoms of asthma differ between patients with and without this mutation.
News Antiviral and Anti-inflammatory Effects of Alpha-1-Antitrypsin in the Treatment of COVID-19
Human alpha-1-antitrypsin (AAT) is a circulating blood glycoprotein that has been used for decades in the treatment of patients with AAT deficiency, lung damage, and emphysema, helping to prevent acute lung injury. Recently, it has been found that AAT also mitigates the course of COVID-19 disease by hindering the entry of the SARS-CoV-2 coronavirus into host cells. This dual antiviral and anti-inflammatory action makes AAT an excellent candidate for COVID-19 treatment.